Researchers at the University of Oxford and the University of Michigan have developed a new type of microrobot that can deliver therapeutics with precision and navigate complex biological terrains. The microrobots, called permanent magnetic droplet-derived microrobots (PMDMs), are made from a biocompatible hydrogel and can be tailored to each clinical scenario. They can carry drugs or therapeutic cells and perform a range of locomotion behaviors under external magnetic control.
Forecast for 6 months: Expect to see the first clinical trials of PMDMs in humans, focusing on drug delivery and tissue repair. Regulatory bodies will begin to review the safety and efficacy of these microrobots, paving the way for their widespread adoption.
Forecast for 1 year: As PMDMs gain traction in the medical community, we can expect to see a surge in research and development of new applications, including cancer treatment and neurology. The first commercial products using PMDMs will likely hit the market, targeting niche markets.
Forecast for 5 years: By 2029, PMDMs will have become a standard tool in the medical arsenal, with widespread adoption in hospitals and clinics. New companies will emerge to develop and commercialize PMDM-based products, leading to increased competition and innovation in the field.
Forecast for 10 years: By 2033, PMDMs will have revolutionized the field of medicine, enabling personalized and targeted treatments for a wide range of diseases. The technology will have expanded beyond medicine, with applications in environmental monitoring, agriculture, and other fields.
